Alexander E, Goldberg L, Das AF, et al. - The efficacy and adverse events of a 5-day oral lefamulin regimen in patients with community-acquired bacterial pneumonia were examined. In this randomized clinical trial, researchers included 738 patients from 99 sites in 19 countries and randomized them 1:1 to receive oral lefamulin (600 mg every 12 hours for 5 days; n = 370) or moxifloxacin (400 mg every 24 hours for 7 days; n = 368). At 96 hours (within a 24-hour window) after the first dose of study drug, the lefamulin group and the moxifloxacin group had the early clinical response rate of 90.8% and 90.8%, respectively. The difference between the two met the noninferiority margin of 10%. Findings thereby establish oral lefamulin as noninferior to oral moxifloxacin for the treatment of community-acquired bacterial pneumonia.